Pharmaceuticals Acquisitions in Colorado

Welsh, Carson, Anderson & Stowe (WCAS) acquired a majority ownership stake in Leiters, an FDA-registered 503B outsourced pharmaceutical compounding provider. WCAS invested alongside health system investors including Intermountain Ventures, Novant Health, Rex Health Ventures, Spectrum Health Ventures and UNC Health, while existing investors — including Kaiser Permanente Ventures, Mayo Clinic, Frazier Healthcare Partners, SV Health Investors and H.I.G. BioHealth Partners — made reinvestments to support Leiters' growth, facility expansion and new product development.

CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.